FrancophonIA/ELRC3.0 huggingface dataset:
English: Darunavir belongs to a group of HIV medicines called ‘protease inhibitors' which work by reducing the amount of HIV in your body to a very low level.
Slovenian: Darunavir sodi v skupino učinkovin, ki jih imenujemo zaviralci proteaze.
English: Based on theoretical considerations REZOLSTA is expected to increase colchicine plasma concentrations.
Slovenian: Glede na teoretična izhodišča je mogoče pričakovati, da zdravilo REZOLSTA zvišuje koncentracijo kolhicina v plazmi.
English: St John's wort (Hypericum perforatum)
Slovenian: ANTIDEPRESIVI zdravila rastlinskega izvora šentjanževka (Hypericum perforatum)
English: Based on theoretical considerations REZOLSTA is expected to increase these sedative/hypnotic plasma concentrations.
Slovenian: Glede na teoretična izhodišča je mogoče pričakovati, da zdravilo REZOLSTA zvišuje koncentracijo navedenih pomirjeval/uspaval v plazmi.
English: Lansoprazole
Slovenian: alfuzosin
English: Based on theoretical considerations REZOLSTA is expected to increase alfentanil plasma concentrations.
Slovenian: Glede na teoretična izhodišča je mogoče pričakovati, da zdravilo REZOLSTA zveča plazemsko koncentracijo alfentanila.
English: Co-administration of REZOLSTA and efavirenz is not recommended.
Slovenian: Sočasna uporaba zdravila REZOLSTA in efavirenza ni priporočljiva.
English: REZOLSTA and tenofovir disoproxil can be used without dose adjustments.
Slovenian: Zdravilo REZOLSTA in dizoproksiltenofovirat je mogoče uporabljati brez prilagajanja odmerkov.
English: During the second trimester of pregnancy, cobicistat Cmax, AUC24h, and Cmin were 50%,
Slovenian: V drugem trimesečju nosečnosti so bile vrednosti Cmax, AUC24h, in Cmin kobicistata za 50%, 63%, oziroma 83% nižje kot v obdobju po porodu.
English: Treatment-naïve darunavir/ritonavir 800/100 mg once daily N = 343
Slovenian: predhodno nezdravljeni darunavir/ritonavir 800/100 mg enkrat na dan n = 343
English: Clinical monitoring is recommended when co-administering REZOLSTA perphenazine, risperidone or thioridazine.
Slovenian: Pri sočasni uporabi zdravila REZOLSTA s perfenazinom, risperidonom ali tioridazinom je priporočljivo klinično spremljanje bolnika.
English: Common vomiting, abdominal pain, abdominal distension, dyspepsia, flatulence
Slovenian: Bolezni prebavil zelo pogosti diareja, navzea pogosti bruhanje, bolečine v trebuhu, napihnjen trebuh, dispepsija, flatulenca občasni akutni pankreatitis, zvišane koncentracije encimov trebušne slinavke
English: Caution is warranted and clinical monitoring is recommended.
Slovenian: Pri sočasni uporabi zdravila REZOLSTA in klonazepama je priporočljivo klinično spremljanje bolnika.
English: Based on theoretical considerations REZOLSTA is expected to increase these anti-neoplastic plasma concentrations.
Slovenian: Glede na teoretična izhodišča je mogoče pričakovati, da zdravilo REZOLSTA zvišuje koncentracijo navedenih antimikotikov v plazmi.
English: The recommended dose of maraviroc is 150 mg twice daily when co-administered with REZOLSTA.
Slovenian: Pri sočasni uporabi zdravila REZOLSTA je priporočeni odmerek maraviroka 150 mg dvakrat na dan. Za več podatkov glejte Povzetek glavnih značilnosti zdravila za maravirok.
English: ANTIANGINA/ANTIARRHYTHMIC Disopyramide
Slovenian: ANTIARITMIKI/ZDRAVILA ZA ZDRAVLJENJE ANGINE PEKTORIS dizopiramid flekainid lidokain (sistemski) meksiletin propafenon
English: REZOLSTA might increase the risk for elevated potassium levels by drospirenone.
Slovenian: Sočasno dajanje zdravila REZOLSTA in drospirenona lahko zveča tveganje za zvišanje koncentracije kalija.
English: Outcomes darunavir/ ritonavir 800/100 mg once daily N = 343
Slovenian: 96. teden izidi darunavir/ ritonavir 800/100 mg enkrat na dan n = 343
English: Dabigatran, ticagrelor to help stop the clumping of platelets in the treatment of patients with a history of a heart attack
Slovenian: avanafil za zdravljenje erektilne disfunkcije dabigatran, tikagrelor preprečevanje zlepljanja trombocitov pri zdravljenju bolnikov, ki so že imeli srčni infarkt naloksegol zdravljenje zaprtja, povzročenega z zdravili za lajšanje bolečin dapoksetin zdravljenje prezgodnje ejakulacije domperidon za preprečevanje slabosti in bruhanja
English: Based on theoretical considerations REZOLSTA may alter norethindrone plasma concentrations.
Slovenian: Glede na teoretična izhodišča je mogoče pričakovati, vpliv zdravila REZOLSTA na plazemske koncentracije noretisterona.
English: This overview was last updated in 05-2018.
Slovenian: Povzetek je bil nazadnje posodobljen 05-2018.
English: Further information on Xultophy can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije za zdravilo Xultophy so na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European public assessment reports..
English: What measures are being taken to ensure the safe and effective use of Xultophy?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Xultophy?
English: Xultophy received a marketing authorisation valid throughout the EU on 18 September 2014.
Slovenian: Za zdravilo Xultophy je bilo 18. septembra 2014 izdano dovoljenje za promet, veljavno po vsej EU.
English: Patients can inject themselves with Xultophy if they have been trained appropriately.
Slovenian: Bolniki si lahko zdravilo vbrizgajo sami, če so bili za to ustrezno usposobljeni.
English: The European Medicines Agency decided that Xultophy's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Xultophy večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Xultophy is given once a day, preferably at the same time each day.
Slovenian: Zdravilo Xultophy se injicira enkrat dnevno, po možnosti vsak dan ob istem času.
English: In the group using insulin degludec it fell from 8.8% to 8.0%.
Slovenian: V skupini, ki je jemala insulin degludek, se je znižala z 8,8 % na 8,0 %.
English: Other information about Xultophy
Slovenian: Druge informacije o zdravilu Xultophy
English: As for all medicines, data on the use of Xultophy are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Xultophy stalno spremljajo.
English: Xultophy (insulin degludec / liraglutide)
Slovenian: Xultophy (insulin degludek/liraglutid)
English: The site of injection should be changed with each injection to avoid changes to the skin (such as thickening) that can make the medicine work less well than expected.
Slovenian: Za vsako injiciranje je treba izbrati drugo mesto na telesu, da se preprečijo spremembe na koži (na primer odebelitev), zaradi česar je lahko učinkovitost zdravila manjša od pričakovane.
English: Side effects on the digestive system occurred in up to 1 in 10 patients and included nausea (feeling sick), diarrhoea, vomiting, constipation, dyspepsia (indigestion), gastritis (inflammation of the stomach), abdominal pain (stomach ache), flatulence (wind), gastroesophageal reflux disease (passage of stomach acid back up towards the mouth), and distension (swelling) of the belly.
Slovenian: Neželeni učinki na prebavila, ki so jih zabeležili pri največ 1 od 10 bolnikov, so vključevali navzejo (siljenje na bruhanje), drisko, bruhanje, zaprtje, dispepsijo (prebavne motnje), gastritis (vnetje želodca), bolečine v trebuhu, flatulenco (vetrove), gastroezofagealno refluksno bolezen (vračanje želodčne kisline v požiralnik) in trebušno distenzijo (napihnjenost).
English: Once-daily injection of Xultophy has been shown to be of benefit in controlling blood glucose in three main studies involving 2,514 patients with type 2 diabetes.
Slovenian: Injiciranje zdravila Xultophy enkrat dnevno se je izkazalo za koristno pri uravnavanju glukoze v krvi v treh glavnih študijah, ki so vključevale 2 514 bolnikov s sladkorno boleznijo tipa 2.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xultophy have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Xultophy upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: For more information about using Xultophy, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Xultophy glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: An overview of Xultophy and why it is authorised in the EU
Slovenian: Pregled zdravila Xultophy in zakaj je odobreno v EU
English: The most common side effect with Xultophy (which may affect more than 1 in 10 people) is hypoglycaemia (low blood glucose).
Slovenian: Najpogostejši neželeni učinek zdravila Xultophy (ki se lahko pojavi pri več kot 1 osebi od 10) je hipoglikemija (nizka raven glukoze v krvi).
English: The company that markets Xultophy will provide educational materials for healthcare professionals, explaining how to use the medicine safely, so as to reduce the risk of medication errors.
Slovenian: Poleg tega bo družba, ki trži zdravilo, priskrbela izobraževalno gradivo za zdravstvene delavce, kjer bo obrazloženo, kako varno uporabljati zdravilo, da se zmanjša tveganje za napake pri njegovi uporabi.
English: Side effects reported with Xultophy are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Xultophy, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: In the group that kept on receiving the GLP-1 agonist, it fell from 7.7% to 7.4%.
Slovenian: V skupini, ki je nadaljevala z jemanjem agonista GLP-1, se je raven znižala s 7,7 % na
English: Xultophy is a medicine that is used for the treatment of type 2 diabetes.
Slovenian: Xultophy je zdravilo, ki se uporablja za zdravljenje sladkorne bolezni tipa 2.
English: It acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food.
Slovenian: To pomeni, da deluje enako kot inkretini (v črevesju proizvedeni hormoni), in sicer tako, da povečuje količino insulina, ki ga kot odziv na zaužito hrano izloči trebušna slinavka.
English: What benefits of Xultophy have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Xultophy izkazalo v študijah?
English: One of the active substances in Xultophy, insulin degludec, is a replacement insulin that acts in the same way as naturally produced insulin and helps glucose enter cells from the blood.
Slovenian: Ena od učinkovin v zdravilu Xultophy, insulin degludek, je nadomestek insulina, ki deluje enako kot naravno tvorjeni insulin in pomaga pri prehodu glukoze iz krvi v celice.
English: Why is Xultophy approved?
Slovenian: Zakaj je bilo zdravilo Xultophy odobreno?
English: The other active substance in Xultophy, liraglutide, belongs to the class of diabetes medicines known as GLP-1 agonists.
Slovenian: Druga zdravilna učinkovina v zdravilu Xultophy, liraglutid, spada v razred zdravil za zdravljenje sladkorne bolezni, znanih kot agonisti GLP-1.
English: The majority of patients treated with Xultophy in these studies achieved control of their blood glucose (HbA1c below 7.0%) and many achieved HbA1c below 6.5%.
Slovenian: Pri večini bolnikov, ki so se v navedenih študijah zdravili z zdravilom Xultophy, se je uravnavanje glukoze v krvi izboljšalo (HbA1c nižji od 7,0 %), pri mnogih pa je bila dosežena raven nižja od 6,5 %.
English: What are the risks associated with Xultophy?
Slovenian: Kakšna tveganja so povezana z zdravilom Xultophy?
English: What is Xultophy and what is it used for?
Slovenian: Kaj je zdravilo Xultophy in za kaj se uporablja?
English: Type 2 diabetes is a disease in which the body does not produce enough insulin to control the level of blood glucose, or the body is unable to use insulin effectively.
Slovenian: Pri sladkorni bolezni tipa 2 telo ne proizvaja dovolj insulina za uravnavanje ravni glukoze v krvi ali pa ga ne more učinkovito izrabiti.
English: Together with diet and exercise, Xultophy is added to treatment with diabetes medicines taken by mouth when these medicines, alone or with other injections, have not controlled blood glucose (sugar) levels.
Slovenian: Skupaj s prehrano in telesno vadbo se zdravilo Xultophy dodaja drugim zdravilom za zdravljenje sladkorne bolezni, ki se jemljejo peroralno, kadar ta zdravila sama ali v kombinaciji z drugimi injekcijami ne nadzorujejo glukoze (sladkorja) v krvi.
English: For the full list of side effects and restrictions with Xultophy, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Xultophy glejte navodilo za uporabo.
English: In all studies, the main measure of effectiveness was the change after 6 months of treatment in the level in the blood of a substance called glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled.
Slovenian: V vseh študijah je bilo glavno merilo učinkovitosti sprememba ravni snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), po šestih mesecih zdravljenja.
English: • The first study involved 1,663 patients whose diabetes was not adequately controlled with the diabetes medicines metformin or metformin and pioglitazone taken by mouth.
Slovenian: • Prva študija je vključevala 1 663 bolnikov s sladkorno boleznijo, ki ni bila ustrezno nadzorovana z zdraviloma za sladkorno bolezen metforminom in pioglitazonom, jemanima peroralno.
English: Xultophy is available as pre-filled disposable pens and can only be obtained with a prescription.
Slovenian: Zdravilo Xultophy je na voljo v obliki napolnjenih peresnikov za enkratno uporabo, predpisovanje in izdaja zdravila pa je le na recept.
English: How does Xultophy work?
Slovenian: Kako zdravilo Xultophy deluje?
English: The average HbA1c level, which was 8.3% at the start, fell to 6.4% after 26 weeks of treatment with Xultophy, compared with 6.9% and 7.0% respectively with insulin degludec and liraglutide.
Slovenian: Začetna povprečna raven HbA1c je bila 8,3 %, po 26 tednih zdravljenja z zdravilom Xultophy pa se je znižala na 6,4 % v primerjavi s 6,9 % pri dodajanju insulina degludeka in 7,0 % pri jemanju liraglutida.
English: The active substances in Xultophy are insulin degludec and liraglutide.
Slovenian: Učinkovini v zdravilu Xultophy sta insulin degludek in liraglutid.
English: It is given as an injection under the skin of the thigh, the upper arm or the abdomen (belly).
Slovenian: Injicira se v podkožje, in sicer v stegno, nadlaket ali trebuh.
English: Adding this medicine to other diabetes medicines offers better control of blood glucose and having an alternative treatment option is valuable in individualising treatment.
Slovenian: Odbor je menil, da jemanje zdravila Xultophy skupaj z drugimi zdravili za zdravljenje sladkorne bolezni prispeva k učinkovitejšemu nadzoru ravni glukoze v krvi in da je ta alternativna možnost lahko koristna pri individualiziranem zdravljenju.
English: Insulin degludec is slightly different from human insulin as it is absorbed more slowly and regularly by the body after an injection and it works for a long time.
Slovenian: Razlika se odraža v počasnejši in rednejši absorpciji v telo po injiciranju ter v dolgotrajnem delovanju.
English: Adding Xultophy to their treatment was compared with adding either of its active substances, insulin degludec or liraglutide.
Slovenian: Dodajanje zdravila Xultophy so primerjali z dodajanjem ene ali druge učinkovine, insulina degludeka ali liraglutida.
English: How is Xultophy used?
Slovenian: Kako se zdravilo Xultophy uporablja?
English: • The third study involved 438 patients whose blood glucose was not adequately controlled by a combination of a GLP-1 agonist (liraglutide or exenatide) and metformin with or without other diabetes medicines taken by mouth.
Slovenian: • Tretja študija je vključevala 438 bolnikov, pri katerih raven glukoze v krvi ni bila zadostno uravnavana z jemanjem kombinacije agonista GLP-1 (liraglutida ali eksenatida) in metformina ne glede na to, ali so jemali druga zdravila za peroralno uporabo za zdravljenje sladkorne bolezni, ali ne. Bolniki, ki jih je vključevala študija, so bodisi nadaljevali z dotedanjim zdravljenjem bodisi prejeli zdravilo Xultophy namesto agonista GLP-1.
English: Average HbA1c at the start was 8.7% in the Xultophy group, and fell after 26 weeks of treatment to 6.9%.
Slovenian: V skupini, ki je jemala zdravilo Xultophy, je bila začetna raven HbA1c 8,7 %, po 26 tednih zdravljenja pa se je znižala na 6,9 %.
English: • The second study involved 413 patients whose blood glucose was not adequately controlled by insulin and metformin with or without other diabetes medicines taken by mouth.
Slovenian: • V drugo študijo je bilo vključenih 413 bolnikov, pri katerih raven glukoze v krvi ni bila zadostno nadzorovana z insulinom in metforminom ne glede na to, ali so jemali druga zdravila za peroralno uporabo za zdravljenje sladkorne bolezni, ali ne. Zdravljenje z zdravilom Xultophy in metforminom so primerjali z zdravljenjem z insulinom degludekom in metforminom.
English: Average HbA1c was 7.8% before patients started to receive Xultophy, and fell after 26 weeks of treatment to 6.4%.
Slovenian: Preden so začeli prejemati zdravilo Xultophy, je bila njihova povprečna raven HbA1c v krvi 7,8 %, po 26 tednih zdravljenja pa se je znižala na 6,4 %.
English: The vaccination schedule depends on the age of the child and should be based on official recommendations:
Slovenian: Shema cepljenja je odvisna od starosti otroka in mora temeljiti na uradnih priporočilih:
English: This was true for five of the six additional polysaccharides in the second study.
Slovenian: To je veljalo tudi za pet od šestih dodatnih polisaharidov v drugi študiji.
English: The full EPAR for Prevenar 13 can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Prevenar 13 je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This is a summary of the European public assessment report (EPAR) for Prevenar 13.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Prevenar 13.
English: Prevenar 13 contains the polysaccharides from 13 different types of S. pneumoniae (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F).
Slovenian: Zdravilo Prevenar 13 vsebuje polisaharide iz 13 različnih vrst bakterije S. pneumoniae (serotipe 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F in 23F).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Prevenar 13 on 9 December 2009.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Prevenar 13, veljavno po vsej Evropski uniji, izdala 9. decembra 2009.
English: The studies compared the immune responses one month after vaccination with the two vaccines.
Slovenian: V študijah so primerjali imunski odziv en mesec po cepljenju z dvema cepivoma.
English: Prevenar 13 is a vaccine.
Slovenian: Zdravilo Prevenar 13 je cepivo.
English: People who have a severe fever should not receive the vaccine until they have recovered, but they can still be given the vaccine if they have a mild infection such as a cold.
Slovenian: Bolniki z visoko vročino ne smejo prejeti cepiva, dokler ne ozdravijo, lahko pa so cepljeni, če imajo blažjo okužbo, kot je prehlad.
English: Other information about Prevenar 13
Slovenian: Druge informacije o zdravilu Prevenar 13
English: What measures are being taken to ensure the safe and effective use of Prevenar 13?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Prevenar 13?
English: In Europe, it is estimated that these are responsible for between 73 and 100% of the cases of invasive disease in children under the age of five years, and at least 50 - 76% of the cases of invasive disease in adults, depending on the country.
Slovenian: Po ocenah so ti serotipi v Evropi odgovorni za približno 73 do 100 % invazivnih okužb pri otrocih, mlajših od pet let, in za najmanj 50 do 76 % primerov invazivne bolezni pri odraslih, odvisno od države.
English: Invasive disease occurs when the bacterium spreads through the body causing serious infections such as septicaemia (blood infection) and meningitis (infection of the membranes around the brain and spine).
Slovenian: Invazivna bolezen nastopi, ko se bakterija razširi po telesu, kar povzroči resne okužbe, kot sta septikemija (okužba krvi) in meningitis (okužba membran, ki obdajajo možgane in hrbtenjačo).
English: A risk management plan has been developed to ensure that Prevenar 13 is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Prevenar 13 je bil pripravljen načrt obvladovanja tveganj.
English: When prescribing Prevenar 13, consideration should be given to the risk of invasive disease and pneumonia in the different age groups, other diseases the vaccinees may have and the type of bacteria in the different geographical areas.
Slovenian: Pri predpisovanju zdravila Prevenar 13 je treba upoštevati tveganje invazivne bolezni in pljučnice pri različnih starostnih skupinah, druge bolezni, ki jih morda ima cepljena oseba, in vrsto bakterije v različnih geografskih območjih.
English: The vaccine is also ‘adsorbed' (fixed) onto an aluminium compound to enhance the immune response.
Slovenian: Cepivo je tudi „adsorbirano“ (vezano) na površino aluminijeve spojine, kar spodbudi boljši imunski odziv.
English: Prevenar 13 is very similar to Prevenar but contains six additional polysaccharides from serotypes which are responsible for between 16 and 60% of the cases.
Slovenian: Cepivo Prevenar 13 je zelo podobno cepivu Prevenar, vendar pa vsebuje šest dodatnih polisaharidov iz serotipov, ki so odgovorni za 16 do 60 % primerov.
English: Adults and children aged two years and above should receive one single dose of Prevenar 13 into the shoulder muscle.
Slovenian: Odrasli in otroci, stari dve leti ali več, naj prejmejo en odmerek cepiva Prevenar 13 v ramensko mišico.
English: In adults, Prevenar 13 was investigated in four main studies.
Slovenian: Pri odraslih so učinkovitost zdravila Prevenar 13 raziskovali v štirih glavnih študijah.
English: For more information about treatment with Prevenar 13, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Prevenar 13 preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: For the prevention of pneumonia, although the use of Prevenar 13 was only investigated in adults over 65 years of age, the CHMP considered that the results could also be applied to younger adults as studies have shown that their immune response is similar or higher than that among adults older than 65.
Slovenian: Kar zadeva preprečevanje pljučnice, je CHMP menil, da je, čeprav je bila uporaba zdravila Prevenar 13 raziskana le pri odraslih, starejših od 65 let, rezultate mogoče upoštevati tudi pri mlajših odraslih, saj so študije pokazale, da je njihov imunski odziv podoben ali večji kot pri odraslih, starejših od 65 let.
English: The CHMP decided that Prevenar 13's benefits are greater than its risks and recommended that it be granted marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila Prevenar 13 večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
English: Prevenar 13 was not shown to affect the immunogenicity of other vaccines routinely given to children.
Slovenian: Zdravilo Prevenar 13 ni vplivalo na imunogenost drugih cepiv, ki jih rutinsko prejemajo otroci.
English: In children below two years of age, the vaccine is given by injection into the thigh muscle.
Slovenian: Pri otrocih, mlajših od dveh let, se cepivo daje z injiciranjem v stegensko mišico.